Formulary Drug Review: Sufentanil Sublingual

Baker, Danial E.

doi:10.1177/0018578719851726

Cited by 3 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…El manejo efectivo y práctico del dolor agudo siempre será uno de nuestros principales objetivos (25) . Los opioides continúan siendo una de las principales opciones para el tratamiento del dolor agudo intenso (6,26) .…”

Section: Sufentanyl Sublingualunclassified

“…Existen cerca de 30 fármacos que se administran por vía sublingual, de los cuales, pocos tienen autorizado su uso clínico o se encuentran en investigación (25) . El inicio de acción es breve, pues Rev Mex Anestesiol.…”

Section: Sufentanyl Sublingualunclassified

“…En la actualidad, queda claro que la nanotecnología ofrecerá innovaciones farmacológicas para desarrollar terapias con mejores resultados, sin embargo, aún existen muchas controversias y ensayos a evaluar (25) .…”

Section: Sufentanyl Sublingualunclassified

See 2 more Smart Citations

Sufentanyl: una opción al paradigma clásico

Barrientos-Aderwald,

Ramírez-Rodríguez,

Contreras-Martínez

et al. 2024

Revista Mexicana De Anestesiología

View full text Add to dashboard Cite

Section: Sufentanyl Sublingualunclassified

See 1 more Smart Citation

Sufentanyl: una opción al paradigma clásico

Barrientos-Aderwald,

Ramírez-Rodríguez,

Contreras-Martínez

et al. 2024

Revista Mexicana De Anestesiología

View full text Add to dashboard Cite

“…Further economic analyses, however, are needed to test this potential benefit and determine its ultimate role. 11,19 Because of its quick onset and sustained analgesia, SST could be used for preprocedural or preemptive pain management because recent evidence reveals that preemptive analgesia is often not optimal in ICU patients requiring procedures. 21 Examples of procedures include endotracheal suction, dressing changes, turning in the ICU, chest tube removal, or chest vest use in respiratory patients.…”

Section: Relevance To Patient Care and Clinical Practicementioning

confidence: 99%

“…In the ED, SST can be used where quick pain relief is needed, but there is no IV access or it cannot be obtained quickly or easily. 19 Also, ED patients with complicated IV access issues can experience prolonged delays in emergency care. 20 SST can also be used in the trauma and burn populations for managing pain associated with dressing changes.…”

Section: Relevance To Patient Care and Clinical Practicementioning

confidence: 99%

Sufentanil Sublingual Tablet: A New Option for Acute Pain Management

et al. 2019

View full text Add to dashboard Cite

Objective: The purpose of this article is to review the safety and efficacy of sufentanil sublingual tablet (SST) and suggest its place in therapy for managing acute pain in patients requiring intravenous (IV) opioids. Data Sources: A MEDLINE/PubMed search was performed (2010 to April 2019) using the following keywords: sufentanil sublingual tablet, sufentanil, opioid, moderate to severe acute pain. Study Selection and Data Extraction Quantification: We included English language articles evaluating SST pharmacology, pharmacokinetics, efficacy, and safety in humans for the treatment of acute pain. Data Synthesis: SST is Food and Drug Administration approved and considered safe and effective for the treatment of acute pain in Risk Evaluation and Mitigation Strategy–certified and medically supervised health care settings. Phase III clinical trials showed a statistically significant decrease in summed pain intensity score when SST was compared with placebo. Relevance to Patient Care and Clinical Practice: SST can be a useful option in patients requiring a parenteral opioid who do not have IV access, or it may be unnecessary or difficult to obtain. Because of its quick onset and sustained analgesia, SST may also be useful for procedural pain in the critically ill, to expedite discharges for outpatient procedures, in emergency departments (EDs), and in the battlefield. Conclusions: SST can satisfy an unmet need in patients with acute pain, who require parenteral opioids, and either have no IV access or require prolonged time to achieve IV access such as patients in outpatient surgical centers, EDs, and the battlefield. During periods of parenteral opioid shortage, SST may provide another option for adequate analgesia.

show abstract

Low-dose sufentanil does not affect tolerance to LBNP-induced central hypovolemia or blood pressure responses during a cold pressor test

Jarrard,

McKenna,

Atkins

et al. 2024

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

Hemorrhage is a leading cause of death in the pre-hospital setting. Since pain often accompanies a hemorrhagic insult, the administered pain medication must not interfere with critical autonomic regulation of arterial blood pressure and vital organ perfusion. The purpose of this study was to test two unique hypotheses: a) sublingual sufentanil (Dsuvia) impairs tolerance to progressive central hypovolemia, and b) sublingual sufentanil attenuates pain sensation and the accompanying cardiovascular responses to a noxious stimulus. Twenty-nine adults participated in this double-blinded, randomized, crossover, placebo-controlled trial. Following sublingual administration of sufentanil (30 μg) or placebo, participants completed a progressive lower-body negative pressure (LBNP) challenge to tolerance, followed by a cold pressor test (CPT) after LBNP recovery. Addressing the first aim, tolerance to LBNP was not different between trials (p = 0.495). Decreases in systolic blood pressure from baseline to the end of LBNP also did not differ between trials (time: p<0.001, trial p=0.477, interaction p=0.587). Finally, increases in heart rate from baseline to the end of LBNP did not differ between trials (time: p < 0.001, trial p= p=0.626, interaction p = 0.424). Addressing the second aim, sufentanil attenuated perceived pain (p < 0.001) in response to the CPT, though the magnitude of the change in mean blood pressure during the CPT (p = 0.078) was not different between trials. These data demonstrate that sublingual sufentanil does not impair tolerance to progressive central hypovolemia. Additionally, sublingual sufentanil attenuates perceived pain, but not the accompanying mean blood pressure responses to the CPT.

show abstract

Formulary Drug Review: Sufentanil Sublingual

Cited by 3 publications

References 11 publications

Sufentanyl: una opción al paradigma clásico

Sufentanyl: una opción al paradigma clásico

Sufentanil Sublingual Tablet: A New Option for Acute Pain Management

Low-dose sufentanil does not affect tolerance to LBNP-induced central hypovolemia or blood pressure responses during a cold pressor test

Contact Info

Product

Resources

About